Monday, October 21, 2013 12:31:15 PM
Celldex Therapeutics, Inc. Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings
OXBT gets a completely new business, the private company gets to go IPO during a booming up market & gain off the appreciation of shares. Win/Win! Looking for $5 tomorrow.
Not on wires yet but in a filing. Should gap up over $3 Monday.
I listened to the CC three times. Seems like they are talking to partners in multiple countries, not only Europe, and are selecting the "RIGHT partner", not a partner. During the last CC the mentioned they were looking for a foreign partner, so to hear that partner(s) are interested in multiply countries sounds awesome. Also, I was very surprised that even for drug candidates 02 & 03, listen to the CC....they are fielding MULTIPLE partner discussions not just a partner discussion. Buying ACRX hand over fist & waiting. Not playing the swings. ACRX has the potential, phase 3 tested solution to Morphine, a $3 billion dollar market. Looking for the NDA to be accepted this month with an FDA in Q3 2014. STRONG BUY.
Says sell says and buy back below $2. Short term catalysts are over.
I feel sorry for the bagholders.
Even Adam F., the worlds biggest AMRN bashers, says this is overdone:
Sit down, I don't want you to pass out from shock. $AMRN sell off today on generic Lovaza ruling is unjustified. Resume run-up to FDA panel.
This looks great!
This is a straight line down peeps.
Guru - any idea what the dates are for shares to convert to equity on the merger? This is one amazing pump job.....from the Goldman equity research shop (Not GS which I first thought), to zacks being paid to pump....to even have Jim Rogers join the board so they can pimp out his name for a free 250k options at 3.52. My guess they are pushing to convert the shares then the dump occurs. Seems like there is a real business here, not sure why they are going about it this way.